Uniphar (LON:UPR) Price Target Raised to GBX 480 at Royal Bank Of Canada

Uniphar (LON:UPR) had its price target hoisted by Royal Bank Of Canada from GBX 470 to GBX 480 in a research note issued to investors on Tuesday, MarketBeat.com reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Several other research firms have also weighed in on UPR. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 375 target price on shares of Uniphar in a research note on Wednesday, July 30th. Shore Capital reaffirmed a “buy” rating on shares of Uniphar in a research report on Thursday, May 29th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of GBX 427.50.

Uniphar Price Performance

Shares of LON UPR opened at GBX 352 on Tuesday. The company has a current ratio of 0.90, a quick ratio of 0.60 and a debt-to-equity ratio of 119.48. The company has a market capitalization of £913.70 million, a price-to-earnings ratio of 1,436.73 and a beta of 0.75. Uniphar has a twelve month low of GBX 163 and a twelve month high of GBX 368. The business has a 50 day simple moving average of GBX 334.96 and a 200-day simple moving average of GBX 286.42.

About Uniphar

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.